Astrazeneca Plc (GB:0A4J)

AstraZeneca (0A4J) Income Statement


AstraZeneca Income Statement

Last quarter (Q4 2022), AstraZeneca's total revenue was $11.21B, a decrease of -6.69% from the same quarter last year. In Q4, AstraZeneca's net income was $901.00M. See AstraZeneca’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Dec 22Dec 21Dec 20Dec 19Dec 18
Total Revenue
$ 44.35B$ 44.35B$ 37.42B$ 26.62B$ 24.38B$ 22.09B
Cost of Revenue
$ 12.39B$ -12.39B$ 12.44B$ 5.30B$ 4.92B$ 4.94B
Gross Profit
$ 31.96B$ 31.96B$ 24.98B$ 21.32B$ 19.46B$ 17.15B
Operating Expense
$ 28.80B$ -28.42B$ 25.11B$ 17.40B$ 18.77B$ 16.64B
Operating Income
$ 3.15B$ 3.54B$ -134.00M$ 3.92B$ 690.00M$ 516.00M
Net Non Operating Interest Income Expense
$ -1.25B$ -1.25B$ -1.23B$ -1.19B$ -1.24B$ -1.23B
Other Income Expense
-$ 225.00M----
Pretax Income
$ 2.50B$ 2.50B$ -265.00M$ 3.92B$ 1.55B$ 1.99B
Tax Provision
$ -792.00M$ 792.00M$ -380.00M$ 772.00M$ 321.00M$ -57.00M
Earnings From Equity Interest Net Of Tax
-$ -5.00M----
Net Income Common Stockholders
$ 3.29B$ 3.29B$ 112.00M$ 3.20B$ 1.33B$ 2.15B
Basic EPS
-$ 2.12----
Diluted EPS
-$ 2.11----
Basic Average Shares
-$ 1.55B----
Diluted Average Shares
-$ 1.56B----
Dividend Per Share
-$ 2.90----
Total Operating Income As Reported
Reported Normalized Basic E P S
Reported Normalized Diluted E P S
Rent Expense Supplemental
--$ 262.00M$ 228.00M$ 208.00M$ 188.00M
Total Expenses
$ 41.20B$ -40.81B$ 37.55B$ 22.70B$ 23.69B$ 21.57B
Net Income From Continuing And Discontinued Operation
$ 3.29B$ 3.29B$ 112.00M$ 3.20B$ 1.33B$ 2.15B
Normalized Income
$ 2.92B$ 1.71B$ -848.66M$ 2.19B$ -441.30M$ -168.89M
Interest Expense
$ 1.33B-$ 1.28B$ 1.27B$ 1.40B$ 1.37B
$ 3.83B$ 3.75B$ 1.01B$ 5.19B$ 2.95B$ 3.36B
$ 9.08B-$ 7.54B$ 8.34B$ 6.71B$ 7.11B
Currency in USD

AstraZeneca Earnings and Revenue History

What's Included in PREMIUM?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis